Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Transitional Cell Carcinoma of the Bladder 1Non-metastatic Muscle Invasive Bladder Cancer 1Infiltrating Bladder Urothelial Carcinoma 1Cone Dystrophy 3 1Carcinoma, Transitional Cell 1Bladder Adenocarcinoma 1

Interventions

Gemcitabine 6Trastuzumab 4Carboplatin 3pembrolizumab 2Pemetrexed 2Paclitaxel 2Cisplatin 2vinflunine 1tucatinib 1relatlimab 1palbociclib 1niraparib 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1cabozantinib 1atezolizumab 1apatorsen 1abemaciclib 1Zoledronic Acid 1Urinary Diversion 1Therapeutics 1Thalidomide 1Sunitinib 1Radiosurgery 1Nivolumab 1Mitomycin 1MART-1 Antigen 1Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urologic Neoplasms × Cystectomy × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡